Related references
Note: Only part of the references are listed.Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Silvio E. Inzucchi et al.
DIABETES CARE (2012)
Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus
Priscilla L. Hollander et al.
DIABETES & VASCULAR DISEASE RESEARCH (2011)
Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin A randomized, 52-week, double-blind, active-controlled noninferiority trial
Michael A. Nauck et al.
DIABETES CARE (2011)
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial
K. Strojek et al.
DIABETES OBESITY & METABOLISM (2011)
THE PARATHYROID GLANDS: WHAT THE ENDOCRINE SURGEON SHOULD KNOW Indian Rhino Club
Nancy D. Perrier
ENDOCRINE PRACTICE (2011)
Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise A randomized, double-blind, placebo-controlled, phase 3 trial
Ele Ferrannini et al.
DIABETES CARE (2010)
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial
Clifford J. Bailey et al.
LANCET (2010)
SGLT2 inhibition - a novel strategy for diabetes treatment
Edward C. Chao et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members
Jian Chen et al.
Diabetes Therapy (2010)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study
Richard E. Pratley et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
James F. List et al.
DIABETES CARE (2009)
A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers Applicability of a novel insulin-independent treatment
John P. H. Wilding et al.
DIABETES CARE (2009)
Defining and Characterizing the Progression of Type 2 Diabetes
Vivian A. Fonseca
DIABETES CARE (2009)
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
David M. Nathan et al.
DIABETES CARE (2009)
Improving efficiency of inferences in randomized clinical trials using auxiliary covariates
Min Zhang et al.
BIOMETRICS (2008)
Rosiglitazone no longer recommended
[Anonymous]
LANCET (2008)
Covariate adjustment for two-sample treatment comparisons in randomized clinical trials: A principled yet flexible approach
Anastasios A. Tsiatis et al.
STATISTICS IN MEDICINE (2008)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin
K. Hermansen et al.
DIABETES OBESITY & METABOLISM (2007)
Regulatory mechanisms of Na+/glucose cotransporters in renal proximal tubule cells
Y. J. Lee et al.
KIDNEY INTERNATIONAL (2007)
Islet β cell failure in type 2 diabetes
Marc Prentki et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Comparison of the glycemic effects of rosiglitazone and pioglitazone in triple oral therapy in type 2 diabetes
Michael T. Tran et al.
DIABETES CARE (2006)
Triple therapy in type 2 diabetes - Insulin glargine or rosiglitazone added to combmiation therapy of sulfonylurea plus metformin in insulin-naive patients
J Rosenstock et al.
DIABETES CARE (2006)
Use and abuse of HOMA modeling
TM Wallace et al.
DIABETES CARE (2004)
Share Paper
